Premium
Combination chemotherapy against B 16 melanoma: bleomycin/vinblastine, bleomycin/cis‐diamminedichloroplatinum, 5‐fluorouracil/BCNU and 5‐fluorouracil/methyl‐CCNU
Author(s) -
Mabel Judith A.,
Merker Philip C.,
Sturgeon Michael L.,
Wodinsky Isidore,
Geran Ruth I.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197810)42:4<1711::aid-cncr2820420409>3.0.co;2-x
Subject(s) - bleomycin , vinblastine , medicine , fluorouracil , pharmacology , chemotherapy , melanoma , combination chemotherapy , oncology , cancer research
Four antitumor drug combinations which are currently in clinical use were evaluated experimentally using the murine B16 melanoma model. Bleomycin plus vinblastine produced an increase in life span over either of the two agents alone against both intraperitoneal and subcutaneous B16. This combination also resulted in a large number of long‐term survivors. Bleomycin plus cis‐platinum produced slight enhancement against subcutaneous B16, but showed no advantage against intraperitoneal B16. The combination of 5‐fluorouracil plus methyl‐CCNU significantly increased survival time against the intraperitoneal tumor, and produced long‐term survivors as well. The combination of 5‐fluorouracil plus BCNU was not more effective than BCNU or 5‐fluorouracil alone. These data were compared with the degree of success reported from the clinics against a variety of solid human neoplasms. Cancer 42:1711–1719, 1978.